- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07736612
A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer
26. srpna 2026 aktualizováno: TingBo Liang, Zhejiang University
A Phase Ib/II Study of the Safety, Tolerability, and Efficacy of a Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer
This study aims to evaluate the safety, tolerability, and efficacy of HRS-2329 in combination with other anti-tumor therapies in participants with advanced pancreatic cancer harboring RAS mutations or amplifications.
Přehled studie
Postavení
Zatím nenabíráme
Intervence / Léčba
Typ studie
Intervenční
Zápis (Odhadovaný)
80
Fáze
- Fáze 2
- Fáze 1
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní kontakt
- Jméno: Tingbo Liang, MD.
- Telefonní číslo: +86 19941463683
- E-mail: liangtingbo@zju.edu.cn
Studijní záloha kontaktů
- Jméno: Yiwen Chen, MD.
- E-mail: yiwenchen0705@126.com
Studijní místa
-
-
Zhejiang
-
Hangzhou, Zhejiang, Čína
- the First Affiliated Hospital, School of Medicine
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Ne
Popis
Inclusion Criteria:
- Age ≥ 18 years.
- Histopathologically confirmed locally advanced or metastatic pancreatic adenocarcinoma (originating from pancreatic ductal epithelium) that is not amenable to curative therapy.
- RAS mutation or amplification detected in tumor tissue or blood (by RAS testing).
Prior anti-tumor therapy:
- For cohort HRS-2329-A: at least one line of standard systemic therapy in the advanced setting;
- For cohorts HRS-2329-B and HRS-2329-C: at most one line of standard systemic therapy in the advanced setting.
- At least one measurable lesion according to RECIST version 1.1 criteria.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
- Life expectancy ≥ 3 months.
- Adequate function of vital organs.
- Use of appropriate contraceptive methods during the study period, and so forth.
- Voluntary participation in this study with signed informed consent, good compliance, and willingness to cooperate with follow-up assessments.
Exclusion Criteria:
- Prior treatment with drugs similar to the investigational product.
- Known presence of central nervous system (CNS) metastases.
- Acute or chronic pancreatitis requiring clinical intervention.
- Gastrointestinal disorders that may affect drug administration/absorption, including but not limited to dysphagia, malabsorption syndrome, refractory nausea, vomiting, or diarrhea, Crohn's disease, and ulcerative colitis.
- Gastrointestinal obstruction, or signs/symptoms of gastrointestinal obstruction; however, patients who have undergone surgical intervention with complete resolution of the obstruction may be considered for screening.
- Concurrent biliary obstruction with risk of biliary tract infection (patients with treatable biliary obstruction may be enrolled if adequate biliary drainage is achieved and the risk of biliary infection is resolved after treatment).
- Third-space fluid collections (e.g., massive pleural effusion, ascites) that cannot be stabilised (i.e., no intervention required after drainage removal) within 2 weeks prior to enrolment; patients with only a small amount of fluid detected by imaging and without clinical symptoms may be enrolled.
- Severe infection within 4 weeks prior to enrolment, such as severe pneumonia, bacteraemia, or infectious complications requiring hospitalisation; unexplained fever >38.5°C within 2 weeks prior to enrolment ; signs/symptoms of infection requiring intravenous antibiotic therapy within 2 weeks prior to enrolment.
- Severe cardiovascular or cerebrovascular diseases.
- Known or suspected interstitial lung disease (isolated imaging findings of interstitial changes are not excluded).
- History of definite neurological or psychiatric disorders, including epilepsy and dementia.
- Non-healing wounds (severe, non-healing, or dehiscent), or unhealed fractures.
- Adverse events from prior therapy not recovered to NCI-CTCAE Grade ≤1 at enrolment .
- History of malignancies other than the primary tumour within 5 years prior to enrolment, with the exception of malignancies with low risk of metastasis and death, such as adequately treated carcinoma in situ of the cervix, basal cell carcinoma, or squamous cell carcinoma of the skin.
- Active hepatitis B infection.
- For Cohort C, conditions that are unsuitable for immunotherapy.
- Known allergy to any component of any of the study drugs to be administered.
- Any other condition that, in the investigator's judgement, may affect the study results or result in premature termination of the study.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Sekvenční přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Arm A
This arm evaluates HRS-2329 in combination with nimotuzumab in participants with advanced pancreatic cancer harboring RAS mutations or amplifications who have received at least one prior line of therapy.
Approximately 6 to 10 participants are planned to be enrolled initially to assess safety and preliminary efficacy, at the prespecified dose of HRS-2329 plus nimotuzumab 400 mg (D1,D8,Q3W).
If the safety at this dose level is acceptable, enrollment may be expanded to 15-20 participants.
During this period, the Safety Monitoring Committee (SMC) may review the cumulative safety and efficacy data and, after discussion, decide whether to adjust the dose, add other dose groups or dosing frequency arms for further exploration, or discontinue this combination regimen.
|
Nimotuzumab is a marketed drug, a recombinant humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR).
Nimotuzumab is administered at 400 mg by intravenous infusion over at least 60 minutes on Days 1 and 8 of each 3-week cycle.
HRS-2329 is a novel, potent, oral pan-RAS inhibitor.
HRS-2329 is given orally (to be swallowed whole, not chewed).
It should be taken orally within 30 minutes after breakfast each morning.
|
|
Experimentální: Arm B
This arm evaluates HRS-2329 and HS-20093 with or without nimotuzumab in participants with advanced pancreatic cancer harboring RAS mutations or amplifications who are treatment-naïve or have received up to one prior line of standard systemic therapy.
Approximately 30 participants are planned to be enrolled.
The prespecified doses are HRS-2329 plus HS-20093, with or without nimotuzumab 400 mg on Day 1 and Day 8 of each 3-week cycle.
The Safety Monitoring Committee (SMC) may review the cumulative safety and efficacy data and, after discussion, decide whether to adjust the dose, add other dose groups or dosing frequency arms for further exploration, or discontinue this combination regimen.
|
Nimotuzumab is a marketed drug, a recombinant humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR).
Nimotuzumab is administered at 400 mg by intravenous infusion over at least 60 minutes on Days 1 and 8 of each 3-week cycle.
HRS-2329 is a novel, potent, oral pan-RAS inhibitor.
HRS-2329 is given orally (to be swallowed whole, not chewed).
It should be taken orally within 30 minutes after breakfast each morning.
HS-20093 is a B7-H3 antibody-drug conjugate (ADC).
|
|
Experimentální: Arm C
Alternative arm: This arm evaluates HRS-2329 and HS-20093 in combination with adebrelimab in participants with advanced pancreatic cancer harboring RAS mutations or amplifications who are treatment-naïve or have received up to one prior line of standard systemic therapy.
Approximately 30 participants are planned to be enrolled.
The prespecified doses are HRS-2329 plus HS-20093 plus adebrelimab 1200 mg Q3W.
The Safety Monitoring Committee (SMC) may review the cumulative safety and efficacy data and, after discussion, decide whether to adjust the dose, add other dose groups or dosing frequency arms for further exploration, or discontinue this combination regimen.
|
Adebrelimab is a recombinant humanized anti-PD-L1 monoclonal antibody injection.
It specifically blocks the binding of PD-1 to PD-L1, thereby terminating the immunosuppressive signals transmitted through PD-1 to T cells.
This enables T cells to re-recognize tumor cells and exert cytotoxic effects, ultimately inhibiting tumor growth.
Adebrelimab injection is administered at 1200 mg by intravenous infusion on Day 1 of each 3-week cycle.
HRS-2329 is a novel, potent, oral pan-RAS inhibitor.
HRS-2329 is given orally (to be swallowed whole, not chewed).
It should be taken orally within 30 minutes after breakfast each morning.
HS-20093 is a B7-H3 antibody-drug conjugate (ADC).
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Objective Response Rate
Časové okno: From enrollment to upto 2 years
|
The proportion of patients whose tumor size shrinks as complete response or partial response, as assessed by RECIST1.1.
|
From enrollment to upto 2 years
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Disease Control Rate (DCR)
Časové okno: From enrollment to upto 2 years
|
defined as the proportion of patients with advanced or metastatic cancer who have achieved a complete response (CR), partial response (PR), or stable disease (SD) as the best overall response, relative to the total number of evaluable patients.
|
From enrollment to upto 2 years
|
|
Duration of Response
Časové okno: From enrollment to upto 2 years
|
defined as the time from the first documented objective response (Complete Response [CR] or Partial Response [PR]) to the first documented disease progression (per RECIST 1.1 criteria) or death due to any cause, whichever occurs first.
|
From enrollment to upto 2 years
|
|
Progression-Free Survival
Časové okno: From enrollment to upto 2 years
|
defined as the time from initiation of treatment until the first documented disease progression per RECIST 1.1 criteria, or death due to any cause, whichever occurs first.
|
From enrollment to upto 2 years
|
|
Overall Survival
Časové okno: From enrollment to upto 2 years
|
defined as the time from initiation of treatment until death from any cause.
|
From enrollment to upto 2 years
|
|
Adverse event
Časové okno: From enrollment to upto 2 years
|
Safety evaluation was done continuously during treatment by using CTCAE 5.0
|
From enrollment to upto 2 years
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia (Odhadovaný)
15. srpna 2026
Primární dokončení (Odhadovaný)
30. srpna 2028
Dokončení studie (Odhadovaný)
30. prosince 2029
Termíny zápisu do studia
První předloženo
27. července 2026
První předloženo, které splnilo kritéria kontroly kvality
27. července 2026
První zveřejněno (Aktuální)
30. července 2026
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
31. srpna 2026
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
26. srpna 2026
Naposledy ověřeno
1. července 2026
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- CAPT08
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
NE
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Ne
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ne
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .